A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

NCT01691898 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

231

Enrollment

INDUSTRY

Sponsor class

Conditions

Follicular Lymphoma
Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Obinutuzumab
DRUG: Pinatuzumab Vedotin
DRUG: Polatuzumab Vedotin
DRUG: Rituximab

Sponsor

Genentech, Inc.